or Try an Advanced Search...

    Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 0.53 3.44% 0.02
    BCLI closed up 3.44 percent on Friday, April 19, 2024, on approximately normal volume. It was able to find support at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical BCLI trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    50 DMA Support Bullish 3.44%
    Outside Day Range Expansion 3.44%
    Wide Bands Range Expansion 3.44%
    Lower Bollinger Band Touch Weakness 3.44%
    Wide Bands Range Expansion -1.63%
    New Downtrend Bearish 0.93%
    50 DMA Support Bullish 0.93%
    Older End-of-Day Signals for BCLI ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA about 15 hours ago
    1.5x Volume Pace about 15 hours ago
    Up 1 ATR about 15 hours ago
    Rose Above Previous Day's High about 15 hours ago
    10 DMA Resistance about 15 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BCLI Chart by TradingView
    Basic chart:

    Profile

    Brainstorm Cell Therapeutics Inc. Description

    Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Bone Stem Cell Parkinson's Disease Multiple Sclerosis Neurodegenerative Diseases Medical Research Amyotrophic Lateral Sclerosis Degenerative Disease Storm Bone Marrow Neurochemistry Neurodegenerative Disorders Induced Stem Cells Adult Stem Cell Cell Product Neuron Mesenchymal Stem Cell Cell Encapsulation Growth Factor Hadassah Medical Center Vascular Endothelial Growth Factor

    Is BCLI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
    Apr 16 BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
    Apr 11 BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
    Apr 11 BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
    Apr 10 BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
    Apr 9 BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
    Apr 9 Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
    Apr 9 BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
    Apr 8 BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
    Apr 1 BrainStorm Cell Therapeutics GAAP EPS of -$0.40 beats by $0.16
    See more BCLI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.373
    52 Week Low 0.134
    Average Volume 1,064,075
    200-Day Moving Average 0.67
    50-Day Moving Average 0.46
    20-Day Moving Average 0.61
    10-Day Moving Average 0.57
    Average True Range 0.10
    RSI (14) 48.98
    ADX 24.94
    +DI 18.11
    -DI 24.28
    Chandelier Exit (Long, 3 ATRs) 0.51
    Chandelier Exit (Short, 3 ATRs) 0.65
    Upper Bollinger Bands 0.75
    Lower Bollinger Band 0.47
    Percent B (%b) 0.21
    BandWidth 45.38
    MACD Line 0.02
    MACD Signal Line 0.04
    MACD Histogram -0.0235
    Fundamentals Value
    Market Cap 26.06 Million
    Num Shares 49 Million
    EPS -0.42
    Price-to-Earnings (P/E) Ratio -1.27
    Price-to-Sales 0.00
    Price-to-Book 65.82
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.77
    Resistance 3 (R3) 0.77 0.69 0.73
    Resistance 2 (R2) 0.69 0.63 0.69 0.72
    Resistance 1 (R1) 0.61 0.59 0.65 0.61 0.70
    Pivot Point 0.53 0.53 0.55 0.53 0.53
    Support 1 (S1) 0.45 0.47 0.49 0.45 0.36
    Support 2 (S2) 0.37 0.43 0.37 0.35
    Support 3 (S3) 0.30 0.37 0.33
    Support 4 (S4) 0.30